Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients

Optimizing treatments for type 2 diabetes mellitus (T2DM) remains an urgent issue. In addition to T2DM treatment strategies, such as glycaemic goals (glucose and glycated haemoglobin ? HbА1c) among different patient populations, the influence of glycaemic variability (GV) on the prognosis of patient...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alina Babenko, Elena Ivanovna Krasilnikova, Nikolay Pavlovich Likhonosov, Anna Pavlovna Likhonosova, Elena Nikolaevna Grineva
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2014
Materias:	continuous glucose monitoring glycaemic variability incretins glp-1 analogues/mimetics dpp-4 inhibitors Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/eff73a7fd76a4619b9da53893fae77f0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:eff73a7fd76a4619b9da53893fae77f0
record_format	dspace
spelling	oai:doaj.org-article:eff73a7fd76a4619b9da53893fae77f02021-11-14T09:00:19ZDifferent antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients2072-03512072-037810.14341/DM2014472-80https://doaj.org/article/eff73a7fd76a4619b9da53893fae77f02014-12-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/6406https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Optimizing treatments for type 2 diabetes mellitus (T2DM) remains an urgent issue. In addition to T2DM treatment strategies, such as glycaemic goals (glucose and glycated haemoglobin ? HbА1c) among different patient populations, the influence of glycaemic variability (GV) on the prognosis of patients with T2DM is also important. According to recent data, GV is associated with cardiovascular complications arising from T2DM. However, although the influence of GV on the development of vascular complications arising from diabetes and underlying mechanisms has been extensively investigated, few studies have investigated the effects of different glucose-lowering medications on GV, and there are even fewer reviews of this topic. This type of analysis is highly relevant, particularly because new classes of antidiabetic medications with potent glucose-dependent insulinotropic effects have been developed. These include groups of drugs that mimic or enhance incretin activity, such as glucagon-like peptide (GLP)-1 analogues/mimetics and dipeptidyl peptidase (DPP)-4 inhibitors. A glucose-dependent mechanism suggests that these groups of antidiabetic medications have beneficial effects on GV. Thus, the current study focusses on the comparative analysis of drugs based on their incretin effects (GLP-1 analogues/mimetics and DPP-4 inhibitors) and оther antidiabetic medications with regard to GV in the patients with T2DM.Alina BabenkoElena Ivanovna KrasilnikovaNikolay Pavlovich LikhonosovAnna Pavlovna LikhonosovaElena Nikolaevna GrinevaEndocrinology Research Centrearticlecontinuous glucose monitoringglycaemic variabilityincretinsglp-1 analogues/mimeticsdpp-4 inhibitorsNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 17, Iss 4, Pp 72-80 (2014)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	continuous glucose monitoring glycaemic variability incretins glp-1 analogues/mimetics dpp-4 inhibitors Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	continuous glucose monitoring glycaemic variability incretins glp-1 analogues/mimetics dpp-4 inhibitors Nutritional diseases. Deficiency diseases RC620-627 Alina Babenko Elena Ivanovna Krasilnikova Nikolay Pavlovich Likhonosov Anna Pavlovna Likhonosova Elena Nikolaevna Grineva Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients
description	Optimizing treatments for type 2 diabetes mellitus (T2DM) remains an urgent issue. In addition to T2DM treatment strategies, such as glycaemic goals (glucose and glycated haemoglobin ? HbА1c) among different patient populations, the influence of glycaemic variability (GV) on the prognosis of patients with T2DM is also important. According to recent data, GV is associated with cardiovascular complications arising from T2DM. However, although the influence of GV on the development of vascular complications arising from diabetes and underlying mechanisms has been extensively investigated, few studies have investigated the effects of different glucose-lowering medications on GV, and there are even fewer reviews of this topic. This type of analysis is highly relevant, particularly because new classes of antidiabetic medications with potent glucose-dependent insulinotropic effects have been developed. These include groups of drugs that mimic or enhance incretin activity, such as glucagon-like peptide (GLP)-1 analogues/mimetics and dipeptidyl peptidase (DPP)-4 inhibitors. A glucose-dependent mechanism suggests that these groups of antidiabetic medications have beneficial effects on GV. Thus, the current study focusses on the comparative analysis of drugs based on their incretin effects (GLP-1 analogues/mimetics and DPP-4 inhibitors) and оther antidiabetic medications with regard to GV in the patients with T2DM.
format	article
author	Alina Babenko Elena Ivanovna Krasilnikova Nikolay Pavlovich Likhonosov Anna Pavlovna Likhonosova Elena Nikolaevna Grineva
author_facet	Alina Babenko Elena Ivanovna Krasilnikova Nikolay Pavlovich Likhonosov Anna Pavlovna Likhonosova Elena Nikolaevna Grineva
author_sort	Alina Babenko
title	Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients
title_short	Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients
title_full	Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients
title_fullStr	Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients
title_full_unstemmed	Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients
title_sort	different antihyperglycaemic drug effects on glycaemic variability in type 2 diabetic patients
publisher	Endocrinology Research Centre
publishDate	2014
url	https://doaj.org/article/eff73a7fd76a4619b9da53893fae77f0
work_keys_str_mv	AT alinababenko differentantihyperglycaemicdrugeffectsonglycaemicvariabilityintype2diabeticpatients AT elenaivanovnakrasilnikova differentantihyperglycaemicdrugeffectsonglycaemicvariabilityintype2diabeticpatients AT nikolaypavlovichlikhonosov differentantihyperglycaemicdrugeffectsonglycaemicvariabilityintype2diabeticpatients AT annapavlovnalikhonosova differentantihyperglycaemicdrugeffectsonglycaemicvariabilityintype2diabeticpatients AT elenanikolaevnagrineva differentantihyperglycaemicdrugeffectsonglycaemicvariabilityintype2diabeticpatients
_version_	1718429563928707072

Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients

Ejemplares similares